Core Viewpoint - Changfeng Pharmaceutical (02652) has announced that its new inhaled nucleic acid drug development project has been selected as a key project under Jiangsu Province's 2025 major science and technology initiative "Innovative Biopharmaceuticals" [1] Group 1: Project Overview - The project focuses on addressing key challenges in the pulmonary delivery of small nucleic acid (siRNA) drugs and aims to advance the translational research and preclinical development of inhaled nucleic acid candidates [1] - The project plans to support the development of inhaled nucleic acid candidates targeting major respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis [1] Group 2: Strategic Importance - The selection of this project is considered strategically significant for the company, further validating the strength of its technological platform [1] - Delivery technology is identified as a critical barrier for siRNA treatments in the lungs, and the company has developed an efficient lung-targeted delivery system that has shown promising therapeutic potential in preclinical studies [1] Group 3: Future Commitment - The recognition from relevant departments and expert reviewers reflects the company's and its partners' capabilities in cutting-edge delivery technology research and development [1] - The company is committed to continuous technological innovation to provide more valuable treatment options for patients and to create sustainable long-term returns for shareholders [1]
长风药业：公司主导的新型吸入式核酸药物开发项目入选2025年江苏省科技重大专项“创新生物药”项目